莫西沙星与左氧氟沙星治疗慢性支气管炎急性发作的药物经济学分析

Pharmacoeconomic analysis of moxifloxacin vs levofloxacin in treatment of acute exacerbations of chronic bronchitis(AECB)

目的:探讨莫西沙星与左氧氟沙星治疗慢性支气管炎急性发作(AECB)的经济效果。方法:采用随机、开放、平行对照试验设计,选择AECB病例126例,其中可评价98例,莫西沙星组(治疗组)50例,予莫西沙星400 mg,qd,疗程10 d;左氧氟沙星组(对照组)48例,给左氧氟沙星400 mg,b id,疗程10 d。对两组疗效和不良反应,运用药物经济学成本-效果分析方法进行评价。结果:莫西沙星与左氧氟沙星治疗AECB的总有效率基本相同,分别为92.00%和87.5%(P>0.05);成本-效果比分别为3.59和0.81(P<0.01)。结论左氧氟沙星的治疗方案为AECB治疗的较佳方案。

Object： To explore the economic efficiency of moxifloxacin vs levofloxacin in the treatment of acute exacerbations of chronic bronchitis （AECB）. Methods： The trial was carried out in a randomized, open and parallel design. 126 patients with AECB were involved. 98 cases evaluated were randomly divided into treat group and control group. 50 patients in treat group were given 400mg moxifloxacin capsule for 10d, while 48 patients in control group were given 400mg levofloxacin capsule twice a day for 10d. Results ： The effective ratios were 92.0% and 87.5% （ P 〉 0.05 ） and the cost - effect ratios were 3.59 and 0.81 for moxifloxacin and levofloxacin, respectively. （P 〈 0.01 ） Conclusion： Levofloxacin is superior to moxifloxacin in the treatment of （ AECB）.